An updated version of Novavax’s COVID-19 vaccine has been approved by Canada’s health agency.

According to a Thursday update on the government’s vaccine portal, Health Canada will replace the older version of the protein-based vaccine, Nuvaxovid XBB.1.5. The new version will include an update to the antigen composition targeting the JN.1 variant.

“After a thorough scientific review Health Canada has approved the company’s JN.1 Variant vaccine,” the agency posted on X, formerly known as Twitter.